Compare Bristol-Myers Squibb Co (BMY) vs Fabrinet (FN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Fabrinet — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Fabrinet trades at $488 (market cap $17.30B). The key difference: Bristol-Myers Squibb Co is far larger — about 6.7× Fabrinet's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Fabrinet pays none. Which is the better fit depends on your goals.
| BMY | FN | |
|---|---|---|
Market Cap | $116.30B | $17.30B |
Sector | Health | Technology |
52-Week High | $62.37 | $746.47 |
52-Week Low | $42.60 | $277.04 |
Enterprise Value | $152.24B | $16.36B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
FN trades at $474.64, up 0.75% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals despite positive fundamental trends, including 39% YoY revenue growth and expanding margins. Analyst consensus remains strongly bullish with a $733 price target, though valuation metrics appear elevated with a P/E of 41.48.
The outlook remains positive given FN's strategic position in AI optical supply chains and capacity expansion plans. Key risks include premium valuation, supply chain constraints, and technical weakness. The company's debt-free balance sheet and hyperscaler relationships provide stability amid growth execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →
